| Id: | acc1924 |
| Group: | 2sens |
| Protein: | IRS-1 |
| Gene Symbol: | IRS1 |
| Protein Id: | P35568 |
| Protein Name: | IRS1_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser312 |
| Site Sequence: | SRTESITATSPASMVGGKPGS |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | MCF7 |
| Disease Info: | |
| Drug: | anisomycin |
| Drug Info: | "Anisomycin is a protein synthesis inhibitor antibiotic derived from Streptomyces species, primarily used in research to study cellular processes such as apoptosis and memory consolidation." |
| Effect: | modulate |
| Effect Info: | Anisomycin stress treatment induces the phosphorylation of IRS-1 Ser(312) through the combined action of mTOR and PKCdelta. |
| Note: | no tumor effct |
| Score: | 3.0 |
| Pubmed(PMID): | 15952059 |
| Sentence Index: | 15952059_4-5 |
| Sentence: | "This paper identifies mechanisms leading to Ser(312) regulation in MCF-7 breast cancer cells. Whereas IGF-I phosphorylation of IRS(312) is PI (phosphatidylinositol) 3-kinase dependent, anisomycin stress treatment requires JNK activation to induce phosphorylation of IRS(312)." |
Sequence & Structure:
MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGHHDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSPSDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPNGYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEPEEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPHLPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQPLLHPPEPKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGMSAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGGGSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGSGESSSTRRSSEDLSAYASISFQKQPEDRQ
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| IRS1-Ser312 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 616 | D | Non-small cell lung cancer/carcinoma | Phosphorylation | 18687633 |
| - | - | D | Polycystic ovary syndrome | Phosphorylation | 15130378 |
| - | - | D | Primitive neuroectodermal tumor | Phosphorylation | 8746448 |
| S | 307 | P | Lung cancer/carcinoma | Phosphorylation | 22348039 |
| S | 616 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
| S | 636 | U | Diabetes mellitus | Phosphorylation | 12765939 |
| S | 636 | U | Pancreatic ductal adenocarcinoma | Phosphorylation | 27014871 |
| - | - | U | Ductal carcinoma in situ | Phosphorylation | 23562473 |
| - | - | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 7542850 |
| S | 1101 | U | Diabetes mellitus | Phosphorylation | 17709744 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | A431 | Imatinib | 5.4277 | - | |
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | A459 | Selumetinib | 6.7584 | - | |
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | A459 | SelumetinibMK2206-1to2 | 7.2394 | - | |
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | A459 | SelumetinibMK2206-3to1 | 6.7346 | - | |
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | A549 | MK2206 | 10.7518 | - | |
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | A549 | PD325901 | 7.0076 | - | |
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | A549 | PD325901 | 2 | - | |
| P35568 | IRS1 | P | Ser312 | TESITATS(ph)PASMVGGKPGSFR | PC-9 | Gefitinib | 6.9462 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
